The best of EcoWatch, right in your inbox. Sign up for our email newsletter!
First Glyphosate Trial, of Thousands, Begins as Plaintiff Fights for His Life
Monsanto may have dropped its name, but it can't drop the thousands of cases being brought against it by cancer sufferers claiming its weed-killer Roundup gave them non-Hodgkin's lymphoma, the first of which goes to trial Monday, CNN reported.
The first plaintiff to get his day in court is Dewayne Johnson, a 46-year-old Bay-area father of two, but for Johnson that is a dubious honor. Johnson is being granted an expedited trial because his doctors say he is nearing death, and California law facilitates speedier trials in such cases.
Johnson worked doing pest management for a county school system and used Roundup 20 to 30 times per year in the line of duty. Now, he has days when lesions cover 80 percent of his body and he is too ill to speak.
"Mr. Johnson is angry and is the most safety-oriented person I know," his attorney Timothy Litzenburg told CNN. "Right now, he is the bravest dude in America. Whatever happens with the trial and his health, his sons get to know that."
Litzenburg also represents "more than 2,000 non-Hodgkin's lymphoma sufferers who used Roundup extensively," he told CNN.
The trial will hinge on whether Roundup's key ingredient glyphosate causes cancer and whether Monsanto failed to adequately warn customers.
Monsanto, for its part, has long insisted on glyphosate's safety.
"More than 800 scientific studies, the U.S. Environmental Protection Agency (EPA), the National Institutes of Health and regulators around the world have concluded that glyphosate is safe for use and does not cause cancer," Scott Partridge, Monsanto's vice president of strategy, said in a statement reported by CNN.
But the World Health Organization's International Agency for Research on Cancer (IARC) ruled in 2015 that glyphosate was "probably carcinogenic to humans" based on studies of exposure in the agricultural sector published in the U.S., Canada and Sweden since 2001 and on laboratory experiments conducted on animals.
In March, a San Francisco judge unsealed documents casting doubt on the legitimacy of the studies finding glyphosate safe. The documents revealed Monsanto employees had ghostwritten glyphosate research for academics to sign and that a senior EPA official had killed a glyphosate review after speaking with Monsanto.Johnson's trial will begin nearly a week after another California judge ruled that the state could not require cancer-risk labels on products containing glyphosate, saying evidence was inconclusive, AgriPulse reported. The new labels were scheduled to be required in July, but the judge's ruling has delayed their roll-out, though it is not the final ruling in the case.
EcoWatch Daily Newsletter
When Paris's Notre Dame caught fire on April 15, the flames threatened more than eight centuries of culture and history. The fire evoked shock, horror and grief worldwide. While the cathedral burned, French President Emmanuel Macron expressed determination to rebuild what the French regard as a sacred site.
By Andrea Germanos
Lawyer and visionary thinker Polly Higgins, who campaigned for ecocide to be internationally recognized as a crime on par with genocide and war crimes, died Sunday at the age of 50.
She had been diagnosed with an aggressive cancer last month and given just weeks to live.
The world's first malaria vaccine was launched in Malawi on Tuesday, NPR reported. It's an important day in health history. Not only is it the first malaria vaccine, it's the first vaccine to target any human parasite.
By Jake Johnson
According to the new research, published in the journal Nature Communications, melting permafrost caused by accelerating Arctic warming would add close to $70 trillion to the overall economic impact of climate change if the planet warms by 3°C by 2100.
The New York City Council last week overwhelmingly passed one of the most ambitious and innovative legislative packages ever considered by any major city to combat the existential threat of climate change.